

## SUPPLEMENTAL MATERIAL

### Supplemental Tables

**Supplemental Table 1: Baseline characteristics of patients with atrial fibrillation (AF) or atrial Flutter (AFL) compared with patients without a history of AF/AFL.**

	History of AF/AFL N=1,116	No History of AF/AFL N=16,044	P-value
Age	66.5 (±7.1)	63.8 (±6.8)	<0.001
Female sex (n%)	294 (26.3)	6128 (38.2)	<0.001
Black or African American(n%)	18 (1.6)	585 (3.6)	<0.001
Baseline BMI	34.1 (±6.4)	31.9 (±6.0)	<0.001
Baseline HbA1c	8.2 (±1.2)	8.3 (±1.2)	0.002
LDL-C (mg/dL)	82 (±34)	88 (±35)	<0.001
Duration of type 2 diabetes	11.7 (±7.8)	11.9 (±7.8)	0.36
Established atherosclerotic cardiovascular disease (n%)	601 (53.9)	6373 (39.7%)	<0.001
History of cerebrovascular disease (n%)	141 (12.6)	1160 (7.2%)	<0.001
History of peripheral arterial disease (n%)	68 (6.1)	957 (6.0%)	0.86
History of congestive heart failure (n%)	378 (33.9)	1346 (8.4%)	<0.001
Current tobacco use (n%)	114 (10.2)	2384 (14.9%)	<0.001
<b>Glucose-lowering therapies:</b>			
Insulin (n%)	482 (43.2)	6531 (40.7%)	0.103
Metformin (n%)	842 (75.4)	13226 (82.4%)	<0.001
Sulfonylurea (n%)	443 (39.7)	6879 (42.9%)	0.038
<b>Cardiovascular therapies:</b>			
Digoxin (n%)	238 (21.3)	107 (0.7%)	<0.001
Amiodarone (n%)	90 (8.1)	43 (0.3%)	<0.001
Beta-blocker (n%)	888 (79.6)	8142 (50.7%)	<0.001
Anticoagulant (n%)	731 (65.5)	359 (2.2%)	<0.001
ACE inhibitor or ARB	941 (84.3)	13009 (81.1)	0.007
Diuretic use (n%)	690 (61.8)	6277 (39.1)	<0.001
Antiplatelet agents (n%)	504 (45.2)	9983 (62.2)	<0.001
Statin (n%)	894 (80.1)	11865 (74.0)	<0.001
Baseline eGFR by CKD-EPI (mL/min/1.73 m <sup>2</sup> )	78.8 (±16.3)	85.7 (±15.8)	<0.001
Median UACR (mg/g)	19.5 (7.6, 67.0)	12.8 (6.0, 41.6)	<0.001
Normoalbuminuria (n%)	664 (60.5)	10980 (69.7)	<0.001
Microalbuminuria (n%)	330 (30.1)	3700 (23.5)	<0.001
Macroalbuminuria (n%)	104 (9.5)	1065 (6.8)	<0.001

Continuous variables are reported as means (standard deviation) unless stated otherwise.

Legend: BMI = body mass index; LDL-C = low density lipoprotein cholesterol